| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | 0 | 0 | 0 | 31.513 | 0 | 0 | 0 |
| Total Income - EUR | - | - | - | 0 | 1.607 | 54 | 31.615 | 350 | 559.670 | 3.586 |
| Total Expenses - EUR | - | - | - | 4.389 | 11.229 | 16.786 | 19.914 | 9.772 | 545.003 | 9.514 |
| Gross Profit/Loss - EUR | - | - | - | -4.389 | -9.621 | -16.732 | 11.700 | -9.422 | 14.667 | -5.928 |
| Net Profit/Loss - EUR | - | - | - | -4.389 | -9.621 | -16.732 | 11.385 | -9.422 | 10.928 | -5.928 |
| Employees | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
Check the financial reports for the company - Novator Pharma S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | 149 | 378.605 | 420.272 | 478.901 | 506.696 | 140 | 668.405 |
| Current Assets | - | - | - | 533 | 15.574 | 29.947 | 124.144 | 84.582 | 596.576 | 1.401.707 |
| Inventories | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | 4 | 14.560 | 23.940 | 67.157 | 68.610 | 61.874 | 969.249 |
| Cash | - | - | - | 528 | 1.014 | 6.008 | 56.987 | 15.972 | 534.702 | 32.634 |
| Shareholders Funds | - | - | - | -4.174 | 7.359 | -9.508 | 22.303 | 12.950 | 23.839 | 17.778 |
| Social Capital | - | - | - | 215 | 21.284 | 20.884 | 40.636 | 40.762 | 40.639 | 40.412 |
| Debts | - | - | - | 4.855 | 386.820 | 460.112 | 580.743 | 578.327 | 572.877 | 2.052.335 |
| Income in Advance | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "2110 - 2110" | |||||||||
| CAEN Financial Year |
2110
|
|||||||||
Comments - Novator Pharma S.r.l.